Neon data highlights epitope spread as key metric for neoantigen vaccines

Interim results from Neon's Phase Ib trial of NEO-PV-01 plus Opdivo nivolumab suggest proof of epitope spread will be a telling readout for neoantigen cancer vaccines. The data also point to tumor microenvironment-based predictors of therapeutic response.

Clinical data trickling in from early movers like Neon Therapeutics Inc. (NASDAQ:NTGN) could define biomarkers and set benchmarks for the crowded neoantigen vaccine field (see "Neo Wave")...